As an oncogene, FGFR1 deletion is less understood, while FGFR2 (10q26) missense mutation may be indicative of anti-FGFR2 inhibitor, as amplification or overexpression of FGFR2 was observed in 4% of triple negative breast cancers [33]. This evidence concerns the gene FGFR2 and triple-negative breast carcinoma.